These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27009878)

  • 1. Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer.
    Zhang F; Duan S; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
    Cancer Sci; 2016 Jun; 107(6):746-54. PubMed ID: 27009878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
    Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
    Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.
    Duan S; Tsai Y; Keng P; Chen Y; Lee SO; Chen Y
    Oncotarget; 2015 Sep; 6(29):27651-60. PubMed ID: 26313152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer.
    Yang L; Zhang F; Wang X; Tsai Y; Chuang KH; Keng PC; Lee SO; Chen Y
    Oncotarget; 2016 Aug; 7(34):55543-55554. PubMed ID: 27765901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
    Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D
    Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer.
    Lee SO; Yang X; Duan S; Tsai Y; Strojny LR; Keng P; Chen Y
    Oncotarget; 2016 Feb; 7(6):6626-38. PubMed ID: 26675547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 blockade attenuates lung cancer tissue construction integrated by cancer stem cells.
    Ogawa H; Koyanagi-Aoi M; Otani K; Zen Y; Maniwa Y; Aoi T
    Sci Rep; 2017 Sep; 7(1):12317. PubMed ID: 28951614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.
    Shen M; Xu Z; Xu W; Jiang K; Zhang F; Ding Q; Xu Z; Chen Y
    J Exp Clin Cancer Res; 2019 Apr; 38(1):149. PubMed ID: 30961670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.
    Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q
    Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma.
    Hao C; Liu G; Tian G
    Ther Adv Respir Dis; 2019; 13():1753466619866097. PubMed ID: 31368411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.
    Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
    Mol Carcinog; 2018 Dec; 57(12):1835-1844. PubMed ID: 30182373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Roles of Curcumin in Sensitising the Cisplatin Effect on a Cancer Stem Cell-Like Population Derived from Non-Small Cell Lung Cancer Cell Lines.
    Abdul Satar N; Ismail MN; Yahaya BH
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33670440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription.
    Liu Y; Wang X; Li W; Xu Y; Zhuo Y; Li M; He Y; Wang X; Guo Q; Zhao L; Qiang L
    Oncogene; 2020 Nov; 39(45):6893-6905. PubMed ID: 32978517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.
    Yang L; Shen M; Xu LJ; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO
    Sci Rep; 2017 Aug; 7(1):7958. PubMed ID: 28801607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness.
    Chen MJ; Wu DW; Wang YC; Chen CY; Lee H
    Sci Rep; 2016 Oct; 6():34933. PubMed ID: 27713506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
    Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.
    Fernandez HR; Gadre SM; Tan M; Graham GT; Mosaoa R; Ongkeko MS; Kim KA; Riggins RB; Parasido E; Petrini I; Pacini S; Cheema A; Varghese R; Ressom HW; Zhang Y; Albanese C; Üren A; Paige M; Giaccone G; Avantaggiati ML
    Cell Death Differ; 2018 Jul; 25(7):1239-1258. PubMed ID: 29651165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.